Monte Rosa Therapeutics, Inc. 8-K

What Happened

• Monte Rosa Therapeutics, Inc. (GLUE) announced on January 8, 2026 that it entered an underwriting agreement with Jefferies LLC, TD Securities (USA) LLC and Piper Sandler & Co. to sell an underwritten public offering consisting of 11,125,000 shares of common stock and, in lieu of shares for certain investors, pre-funded warrants to purchase 1,375,000 shares. The public offering price is $24.00 per common share and $23.9999 per pre-funded warrant. The underwriters have a 30-day option to buy up to an additional 1,875,000 shares. The offering is expected to close on or about January 12, 2026, subject to customary conditions.

Key Details

• Offering size: 11,125,000 common shares + pre-funded warrants for 1,375,000 shares; up to 1,875,000 additional shares available to underwriters (30-day option).
• Price and proceeds: $24.00 per common share ($23.9999 per pre-funded warrant); estimated net proceeds approximately $281.6 million (excluding any exercise of the option).
• Warrant terms: Pre-funded warrants have a $0.0001 exercise price, are exercisable at issuance, do not expire, and include customary ownership limits (default 4.99%, holder may elect up to 19.99% with notice).
• Use of proceeds: fund advancement of MRT-8102 for chronic inflammatory diseases (including atherosclerotic cardiovascular disease), continued development of the QuEENTM platform and discovery programs, and general corporate purposes. The company expects cash and equivalents to fund operations into 2029.

Why It Matters

• This offering raises material capital for Monte Rosa’s drug development programs and platform work, extending its reported cash runway into 2029.
• Investors should note potential dilution from the issued shares, exercise of pre-funded warrants, and any overallotment/option shares purchased by underwriters.
• The deal is being conducted off the company’s shelf registration (Form S-3, effective March 31, 2025) and includes customary representations, indemnities and legal opinions.